CVS/pharmacy supporting medical research for ALS cure via in-store fundraiser
WOONSOCKET, R.I. — CVS/pharmacy has announced the launch of its annual in-store Advancing Medical Research fundraising campaign to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS).
"As a pharmacy innovation company that is committed to helping people on their path to better health, CVS Caremark supports organizations and medical research that address important healthcare issues," stated Jon Roberts, EVP for CVS Caremark and honorary chair of the Advancing Medical Research Campaign. "For the past 11 years, we've been able to make a significant impact in advancing ALS research with support from our colleagues and customers. Through the Advancing Medical Research campaign, we continue to make a difference in the lives of those who are living with ALS and support groundbreaking developments to help bring us one step closer to ending this devastating disease."
Funds raised through the campaign will benefit the ALS Therapy Alliance, a national nonprofit organization dedicated to advancing ALS research. Supporters of the 2013 campaign can donate $1 or $3 at the register in CVS/pharmacy locations nationwide and online at www.cvs.com/als through June 29.
ALS is a neurodegenerative disorder that is characterized by progressive degeneration of motor nerves in the brain and spinal cord, typically leading to paralysis and death within four to six years. There is no known cause or cure for ALS, which affects approximately 30,000 Americans, with 5,600 new cases diagnosed nationwide each year.
But a new research grant, funded by CVS/pharmacy, is exploring gene silencing therapies that aim to end the progression of ALS in patients and provide new leads for solving other degenerative disorders.
CVS/pharmacy has raised more than $30 million in support of ALS research over the past 11 years. Through the Advancing Medical Research campaign, CVS/pharmacy will continue to help ATA drive medical research, including the development of groundbreaking gene silencing therapies, with the goal to end ALS.